Filing Details
- Accession Number:
- 0001209191-23-003293
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-13 16:50:44
- Reporting Period:
- 2023-01-11
- Accepted Time:
- 2023-01-13 16:50:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1815442 | Kymera Therapeutics Inc. | KYMR | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1628098 | Atlas Venture Fund X, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1742765 | Atlas Venture Associates X, Llc | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1742766 | Atlas Venture Associates X, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1759241 | Atlas Venture Opportunity Fund I, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1780065 | Atlas Venture Associates Opportunity I, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1780066 | Atlas Venture Associates Opportunity I, Llc | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-01-11 | 21,683 | $29.96 | 5,045,242 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-01-11 | 6,071 | $29.96 | 911,740 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2023-01-12 | 77,128 | $30.29 | 4,968,114 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-01-12 | 21,592 | $30.29 | 890,148 | No | 4 | S | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | See footnote |
Footnotes
- Shares were sold pursuant to a Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $29.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (5).
- These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
- The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.65 inclusive.
Billionaire Hedge Funds
